[
    [
        {
            "time": "2020-08-13",
            "original_text": "新冠抗体试剂紧急使用授权突被取消！安图生物业绩速降大股东“套现”前途凉凉 盈利能力下降",
            "features": {
                "keywords": [
                    "新冠抗体试剂",
                    "紧急使用授权",
                    "取消",
                    "安图生物",
                    "业绩速降",
                    "大股东套现",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.75,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "新冠抗体试剂紧急使用授权突被取消！安图生物业绩速降大股东“套现”前途凉凉 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        }
    ]
]